Anti‐PD1 monoclonal antibodies leads to lower overall survival† compared with anti‐CTLA4 monoclonal antibodies (high certainty).
Anti‐PD1 monoclonal antibodies leads to lower progression‐free survival† compared with anti‐CTLA4 monoclonal antibodies (high certainty).
Anti‐PD1 monoclonal antibodies leads to higher tumour response compared with anti‐CTLA4 monoclonal antibodies (high certainty).
Anti‐PD1 monoclonal antibodies may leads to lower toxicity (≥ G3) compared with anti‐CTLA4 monoclonal antibodies (low certainty).
The review found no eligible studies for this question.
Anti‐CTLA4 monoclonal antibodies with leads to lower progression‐free survival† compared with without anti‐PD1 monoclonal antibodies (high certainty).
Anti‐CTLA4 monoclonal antibodies with leads to higher tumour response compared with without anti‐PD1 monoclonal antibodies (high certainty).
Anti‐CTLA4 monoclonal antibodies with showed no clear difference in toxicity (≥ G3) compared with without anti‐PD1 monoclonal antibodies (low certainty).
Anti‐PD1 monoclonal antibodies leads to lower overall survival† compared with chemotherapy (high certainty).
Anti‐PD1 monoclonal antibodies probably leads to lower progression‐free survival† compared with chemotherapy (moderate certainty).
Anti‐PD1 monoclonal antibodies leads to higher tumour response compared with chemotherapy (high certainty).
Anti‐CTLA4 monoclonal antibodies plus chemotherapy probably leads to lower progression‐free survival† compared with chemotherapy (moderate certainty).
Anti‐CTLA4 monoclonal antibodies plus chemotherapy showed no clear difference in tumour response compared with chemotherapy (moderate certainty).
Anti‐CTLA4 monoclonal antibodies plus chemotherapy probably leads to higher toxicity (≥ G3) compared with chemotherapy (moderate certainty).
Anti‐CTLA4 monoclonal antibodies plus chemotherapy showed no clear difference in overall survival† compared with chemotherapy (low certainty).